Johnson and Johnson

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

6 days ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

J&J’s $130M gene therapy bet flunks rare retinal disease trial

1 month ago talkbio0Tagged bota-vec, Disorder of eye, Failure (biologic function), gene therapy, Infrequent, Investments, Johnson and Johnson, loss treatment, Phase 3, Vision, X-linked retinitis pigmentosa

Johnson & Johnson, gene therapy, bota-vec, X-linked retinitis pigmentosa, Phase 3 failure, vision loss treatment, rare eye disease, $130 million investment

J&J brushes off tariff headwinds with raised forecast, oncology surge

2 months ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

3 months ago talkbio0Tagged Carvykti, competition, Facility (object), Investments, J&J, Johnson and Johnson, Multiple Myeloma, production

Carvykti, Johnson and Johnson, Investments, J&J, Facility (object), Multiple Myeloma, production, competition

Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach

3 months ago talkbio0Tagged Bioepis, Biosimilars, Contract agreement, Johnson and Johnson, Pyzchiva, Samsung, Stelara, ustekinumab

Johnson & Johnson, Samsung Bioepis, Stelara, biosimilar, lawsuit, contract breach, ustekinumab, Pyzchiva

J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal

4 months ago talkbio0Tagged Acquisition, Caplyta, Drug Industry, Duato, Intra-Cellular Therapies, Joaquin, Johnson and Johnson, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A

Johnson & Johnson’s Darzalex and Spravato Achieve Milestones: Darzalex Leads Sales, Spravato Surpasses $1 Billion Revenue

5 months ago talkbio0Tagged Darzalex, Johnson and Johnson, Mental Depression, Multiple Myeloma, Pharmaceutical Sales, Revenue Milestones, Spravato

Johnson & Johnson, Darzalex, Spravato, Pharmaceutical Sales, Multiple Myeloma, Depression Treatment, Revenue Milestones

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion to Strengthen Neuroscience Portfolio

5 months ago talkbio0Tagged Acquisition, Biological Factors, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Biopharmaceutical

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

5 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Bipolar Depression, Schizophrenia, Major Depressive Disorder

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

5 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Caplyta, Lumateperone, Schizophrenia, Bipolar Depression, Major Depressive Disorder